Gene Therapy - Worldwide Market Challenges & Opportunities
BizAcumen, Inc.
November 1, 2009 177 Pages - SKU: BZAC2521928
|
|
Gene therapy promises to be one of the most important frontiers in medicine. Although no significant achievements for curing disease have been achieved, the future seems to hold significant potential in terms of developing such approaches. Advancements in gene therapy have provided useful data, which has helped in understanding the pathogenesis of diseases. The discipline heralds a significant potential for the biotechnology industry over the very long term, as the approach moves from research labs to clinical trials. Proteins and monoclonal antibodies have revolutionized the treatment of a wide variety of diseases, and gene-based therapies that deliver the DNA sequences encoding proteins and antibodies signify the next big step in the evolution of biopharmaceuticals. Gene therapy market is still in the experimental stages with success yet to be achieved in developing completely curative therapeutic drugs.
These and other market data and trends are presented in "Gene Therapy: Worldwide Market Challenges & Opportunities" by BizAcumen LLC. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
|
- 1. METHODOLOGY
- Study Reliability and Reporting Limitations
- Disclaimers
- Quantitative Techniques & Reporting Level
- 2. MARKET DYNAMICS
- Future - On a Promising Note
- Market Predictions Thrive On
- China - First to Hit the Market
- Counting on the Success Factors
- Global Market Analysis
- 3. KEY ISSUES/TRENDS
- Factors Influencing Gene Therapy Future Development
- Human Genome Analysis
- Gene Therapy - The Next Generation Cardiovascular Therapy
- Public Support for Gene Therapy
- RNAi Bode Bright Prospects
- Factors Hampering Market Growth
- Stringent Regulatory Laws in US and Europe Prolongs Gene Therapy Development
- Identifying Genetic Fault
- Immune Response
- Delivering Genetic Materials into Patient Cells
- Multigene Disorders
- Side Effects
- Push Towards Germline Gene Transfer
- Technical Limitations
- 4. THE GLOBAL LANDSCAPE
- Alliances and Acquisitions - Strategy to Success
- Patent Pooling: Yet Another Obstacle
- Commercialization: A Road Uphill
- Time Line in Gene Therapy Drug Development
- Target Diseases and Players Involved
- Key Players by Application Area
- Various Gene Therapy Products Under Development (2007)
- Gene Therapy Industry in Europe and the US - A Comparison
- 5. REVIEW OF MAJOR MARKETS
- United States
- Regulatory Environment
- Food and Drug Administration
- FDA Requires Additional Toxicology and Biodistribution Studies
- CBER
- IRB and IBC
- NIH
- Europe
- Germany and UK- The Hub of European Gene Therapy Market
- Regulatory Environment
- Gene Therapy Advisory Committee
- European Society of Gene and Cell Therapy (ESGCT)
- Study of Regulatory Environment in Select European Countries
- United Kingdom
- Medicines and Healthcare Products Regulatory Agency
- Germany
- Italy
- Sweden
- The Netherlands
- Switzerland
- Japan
- Asia-Pacific
- World's First Gene Therapy Medicine Approved in China
- Prospects for Gendicine
- Competition
- Gene Therapy Formulations under Clinical Trials by Select Company in China
- Rest of World
- 6. PRODUCT FACTS
- Vector
- Gene Cassette
- Target cells
- 7. GENE THERAPY FOR DISEASE TREATMENT
- Gene Therapy for Cancer Treatment
- Gene Transfer and Gene Therapeutic Concepts in Cancer
- Competitive Landscape in Cancer Gene Therapy
- Gene Therapy Mechanism in Cancer
- Advantages Over Chemotherapy
- Developments in Cancer Gene Therapy
- P53 Gene Therapy - A Novel Approach in Cancer Treatment
- Gendicine - From Concept to Reality
- Vaccines
- Gene Therapy for Cardiovascular Disease
- Cardiovascular Gene Therapy Products under Trial
- Gene Therapy for Cystic Fibrosis Disease
- Gene Therapy for Haemophilia B
- Gene Therapy for AIDS/HIV
- Gene Therapy for Parkinson’s Disease
- The Disease
- Therapy
- 8. REGULATORY ENVIRONMENT
- Gene therapy and Regulatory Environment
- Gene Patents - An Overview
- 9. CORPORATE DEVELOPMENTS
- International Consolidated to Acquire China Gene
- Ark Therapeutics to Acquire Lymphatix
- Oxford BioMedica Obtains Rights for RNAi Technology
- Gene Bridges Inks Licensing Agreement with Genencor
- AMT Enters into R&D Agreement with NIH
- VGX Inks Supply Agreement with a U.K. Consortium
- Researchers Develop Synthetic Gene Vectors to Reduce Body Immune Responses
- Cardium Therapeutics Receives Fast Track Designation for Generx™
- Oxford Biomedica’s ProSavin Enters Phase I/II Trial
- Lentigen Acquires Gene Delivery Technology from Cell Genesys
- VIRxSYS Acquires SMaRT™ RNA Technology
- Gene Logic Divests Genomics Assets
- Genzyme Inks Agreement with Ceregene
- Silence Therapeutics Extends Agreement with Quark
- Benda Inks HIV Vaccine Joint Venture with DNAVEC
- Research Dynamics Bags Contract for Multicenter Clinical Study
- Thermo Fischer Collaborates with Lentigen to Develop Gene- Silencing Technology
- Fovea Enters into Collaboration with GENZYME Corporation
- Oxford BioMedica Inks Licensing Agreement with Children’s Hospital
- Sigma and Oxford Sign Joint License Agreement for LentiVector Technology
- Benda Attains Additional Stake in SiBiono
- Oxford BioMedica Acquires Oxxon
- Oxford BioMedica and Sanofi-Aventis Agrees to Co-Develop and Market TroVax
- Illumina Completes Acquisition of Solexa
- Illumina Brings Digital Gene Expression Applications
- MolMed Develops Gene Therapy Based Treatment for Skin Cancer
- Santaris Pharma Develops New Therapy to Lower Cholesterol Level
- Researchers Develop Gene Therapy for Severe Burns
- 10. MAJOR PLAYERS
- AnGes MG, Inc. (Japan)
- Cell Genesys (US)
- GenVec (US)
- Genzyme Corporation (US)
- Introgen Therapeutics, Inc. (US)
- Oxford BioMedica (UK)
- Shenzhen SiBiono GeneTech Co., Ltd (China)
- Targeted Genetics Corp. (US)
- Transgene (France)
- Urigen Pharmaceuticals, Inc. (US)
- Vical, Inc. (US)
- EXHIBITS
- Table 1: Global Gene Therapy Market for the Period 2007-2015 (Sales in US$ Million)
- Table 2: Percentage Breakdown of Gene Therapy Clinical Trails by Disease/Application Area in the World - 2007
- Table 3: Percentage Breakdown of Gene Therapy Clinical Trials by Gene Type Transferred in the World - 2007
- Table 4: Percentage Breakdown of Gene Therapy Clinical Trials by Vector Type in the World - 2007
- Table 5: Gene Therapy Clinical Trials by Develpment Phase in the World - 2007
- Table 6: Percentage Breakdown of Gene Therapy Clinical Trials by Geographic Region - 2007
- Table 7: Percentage Breakdown Gene Therapy Clinical Trials by Country in Europe - 2007
- COMPANIES PROFILED
Share this report
Other tasks Related Markets Gene Therapy Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
